Dr Adam Lawson and colleagues from England examined the morbidity and mortality of patients with severe fibrosis secondary to Hepatitis C virus infection, within a population unbiased by tertiary referral.
|The probability of survival without liver transplantation was 97% at 1 year|
|Journal of Hepatology|
The team identified 150 Hepatitis C virus infected patients from the Trent Hepatitis C virus study with a liver biopsy taken before 2002 demonstrating severe fibrosis.
Follow-up data were extracted from the database and hospital records.
Median follow-up was 51months.
The team identified 131 patients with no prior history of decompensation.
Of these, 25 died and 8 were transplanted after a median interval of 42 months.
The probability of survival without liver transplantation was 97%, 88%, and 78% at 1, 3, and 5 years, respectively.
The researchers diagnosed hepatocellular carcinoma and/or decompensation in 33 patients, after a median interval of 41 months.
The team found that combination antiviral therapy was associated with improved survival.
Prognosis was not affected by the Ishak stage at index biopsy.
The team observed a worse prognosis for the 19 patients with previous decompensation, of which 17 had either died, and 2 were transplanted.
Dr Lawson's team concluded, "This study demonstrates that severe liver fibrosis secondary to Hepatitis C is associated with a poor prognosis."
"That may be improved following combination antiviral treatment."